Table 3 Recommended adjustment of clinical doses for patients undergoing pharmacogenetic intervention (PharmG+)
From: A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments
Antipsychotic | Standard clinical dose | CYP1A2 | CYP2D6 | CYP2C19 | CYP3A5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PM | IM | UM | PM | IM | UM | PM | IM | PM | IM | UM | ||
Clozapine | 150–900 mg/day | <25–50% | NC | >25–30% | <25–30% | NC | ||||||
Olanzapine | 7.5–30 mg/day | <25–50% | NC | >25–30% | ||||||||
Risperidone | 3–12 mg/day | <25–30% | Gradual | >25–30% | ||||||||
Haloperidol | 10–20 mg/day | <50% | <10–20% | >25–30% | ||||||||
Aripiprazole | 10–30 mg/day | <25–50% | Gradual | >25–30% | ||||||||
Quetiapine | 300–750 mg/day | <25–50% | <10–20% | >25–30% | ||||||||
Ziprasidone | 80–160 mg/day | <5–50% | <10–20% | >25–30% | ||||||||
